Medical Editor: John P. Cunha, DO, FACOEP
Mivacron (mivacurium chloride) Injection is a short-acting, nondepolarizing skeletal muscle relaxant for intravenous (IV) administration used for inpatients and outpatients, as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Common side effects of Mivacron include:
- skin flushing or redness,
- transient low blood pressure,
- transient rapid heart rate,
- muscle spasm,
- injection site reactions,
- wheezing, or
- severe allergic reaction
Doses of Mivacron are individualized and based on the presence of significant kidney, liver, or cardiovascular disease, obesity, asthma, reduction in plasma cholinesterase activity, and the presence of inhalational anesthetic agents, among other factors. Mivacron may interact with inhalational anaesthetics used at the same time, other non-depolarising neuromuscular blocking agents, antibiotics, magnesium salts, lithium, local anesthetics, procainamide, quinidine, oral contraceptives, glucocorticoids, monoamine oxidase inhibitors, drugs that irreversibly inhibit plasma cholinesterase, phenytoin, or carbamazepine. Tell your doctor all medications and supplements you use. During pregnancy, Mivacron should be administered only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Mivacron (mivacurium chloride) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Observed In Clinical Trials
MIVACRON (a mixture of three stereoisomers) was well tolerated during extensive clinical trials in inpatients and outpatients. Prolonged neuromuscular block, which is an important adverse experience associated with neuromuscular blocking agents as a class, was reported as an adverse experience in three of 2074 patients administered MIVACRON. The most commonly reported adverse experience following the administration of MIVACRON was transient, dosedependent cutaneous flushing about the face, neck, and/or chest. Flushing was most frequently noted after the initial dose of MIVACRON and was reported in about 25% of adult patients who received 0.15 mg/kg MIVACRON over 5 to 15 seconds. When present, flushing typically began within 1 to 2 minutes after the dose of MIVACRON and lasted for 3 to 5 minutes. Of 105 patients who experienced flushing after 0.15 mg/kg MIVACRON, two patients also experienced mild hypotension that was not treated, and one patient experienced moderate wheezing that was successfully treated.
Overall, hypotension was infrequently reported as an adverse experience in the clinical trials of MIVACRON. One of 332 (0.3%) healthy adults who received 0.15 mg/kg MIVACRON over 5 to 15 seconds and none of 37 cardiac surgery patients who received 0.15 mg/kg MIVACRON over 60 seconds were treated for a decrease in blood pressure in association with the administration of MIVACRON. One to two percent of healthy adults given greater than or equal to 0.2 mg/kg MIVACRON over 5 to 15 seconds, 2% to 3% of healthy adults given 0.2 mg/kg over 30 seconds, none of 100 healthy adults given 0.25 mg/kg as a divided dose (0.15 mg/kg followed in 30 seconds by 0.1 mg/kg), and 2% to 4% of cardiac surgery patients given greater than or equal to 0.2 mg/kg over 60 seconds were treated for a decrease in blood pressure. None of the 63 children who received the recommended dose of 0.2 mg/kg MIVACRON was treated for a decrease in blood pressure in association with the administration of MIVACRON.
The following adverse experiences were reported in patients administered MIVACRON (all events judged by investigators during the clinical trials to have a possible causal relationship):
Incidence Greater Than 1%
Incidence Less Than 1%
Hypotension, tachycardia, bradycardia, cardiac arrhythmia, phlebitis
Bronchospasm, wheezing, hypoxemia
Rash, urticaria, erythema, injection site reaction
Prolonged drug effect
Observed In Clinical Practice
Based on initial clinical practice experience in patients who received MIVACRON, spontaneously reported adverse events are uncommon. Some of these events occurred at recommended doses and required treatment.
From post-marketing surveillance, MIVACRON has been associated with reports of anaphylactic/anaphylactoid reactions which in some cases have been life-threatening and fatal. Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency (see WARNINGS AND PRECAUTIONS). In some of these reports, sensitivity to MIVACRON was confirmed using skin test procedures.
Other adverse reaction data from clinical practice are insufficient to establish a causal relationship or to support an estimate of their incidence. These adverse events include:
Diminished drug effect, prolonged drug effect
Hypotension (rarely severe), flushing
Read the entire FDA prescribing information for Mivacron (Mivacurium Chloride Injection)
© Mivacron Patient Information is supplied by Cerner Multum, Inc. and Mivacron Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.